Results
|
11261.
|
|
|
11262.
|
|
|
11263.
|
|
|
11264.
|
|
|
11265.
|
Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. [electronic resource] by
- Li, Bohua
- Zhao, Lei
- Guo, Huaizu
- Wang, Chong
- Zhang, Xunming
- Wu, Lan
- Chen, Lin
- Tong, Qing
- Qian, Weizhu
- Wang, Hao
- Guo, Yajun
Producer: 20100105
In:
Blood vol. 114
Availability: No items available.
|
|
11266.
|
|
|
11267.
|
|
|
11268.
|
Refractory thrombotic thrombocytopenic purpura and membranoproliferative glomerulonephritis successfully treated with rituximab: a case associated with hepatitis C virus infection. [electronic resource] by
- Mak, S K
- Lo, K Y
- Lo, M W
- Chan, S F
- Lo, K C
- Wong, Y Y
- Tong, Gensy M W
- Wong, P N
- Ma, Edmond S K
- Wong, Andrew K M
Producer: 20090716
In:
Hong Kong medical journal = Xianggang yi xue za zhi vol. 15
Availability: No items available.
|
|
11269.
|
A single cycle of rituximab for the treatment of severe pemphigus. [electronic resource] by
- Joly, Pascal
- Mouquet, Hugo
- Roujeau, Jean-Claude
- D'Incan, Michel
- Gilbert, Danièle
- Jacquot, Serge
- Gougeon, Marie-Lise
- Bedane, Christophe
- Muller, Ralf
- Dreno, Brigitte
- Doutre, Marie-Sylvie
- Delaporte, Emmanuel
- Pauwels, Christine
- Franck, Nathalie
- Caux, Frédéric
- Picard, Catherine
- Tancrede-Bohin, Emmanuelle
- Bernard, Philippe
- Tron, François
- Hertl, Michael
- Musette, Philippe
Producer: 20070813
In:
The New England journal of medicine vol. 357
Availability: No items available.
|
|
11270.
|
Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. [electronic resource] by
- Browning, Rebekah L
- Geyer, Susan M
- Johnson, Amy J
- Jelinek, Diane F
- Tschumper, Renee C
- Call, Timothy G
- Shanafelt, Tait D
- Zent, Clive S
- Bone, Nancy D
- Dewald, Gordon W
- Lin, Thomas S
- Heerema, Nyla A
- Grever, Michael R
- Kay, Neil E
- Byrd, John C
- Lucas, David M
Producer: 20080226
In:
Leukemia research vol. 31
Availability: No items available.
|
|
11271.
|
|
|
11272.
|
|
|
11273.
|
|
|
11274.
|
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. [electronic resource] by
- Pescovitz, Mark D
- Greenbaum, Carla J
- Krause-Steinrauf, Heidi
- Becker, Dorothy J
- Gitelman, Stephen E
- Goland, Robin
- Gottlieb, Peter A
- Marks, Jennifer B
- McGee, Paula F
- Moran, Antoinette M
- Raskin, Philip
- Rodriguez, Henry
- Schatz, Desmond A
- Wherrett, Diane
- Wilson, Darrell M
- Lachin, John M
- Skyler, Jay S
Producer: 20091207
In:
The New England journal of medicine vol. 361
Availability: No items available.
|
|
11275.
|
Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases. [electronic resource] by
- Mai, Hoa L
- Cesbron, Anne
- Brouard, Sophie
- Blanchol, Gilles
- Cantarovich, Diego
- Dantal, Jacques
- Hourmant, Maryvonne
- Lino, Marie
- Meurette, Aurelie
- Gosselin, Morgane
- Abbadie, Odette
- Soulillou, Jean-Paul
- Giral, Magali
Producer: 20100707
In:
Clinical transplants p. 361-8
Availability: No items available.
|
|
11276.
|
|
|
11277.
|
High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma. [electronic resource] by Producer: 20101108
In:
Leukemia & lymphoma vol. 51
Availability: No items available.
|
|
11278.
|
Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. [electronic resource] by
- Hoyer, Bimba F
- Mumtaz, Imtiaz M
- Loddenkemper, Konstanze
- Bruns, Anne
- Sengler, Claudia
- Hermann, Kay-Geert
- Maza, Sofiane
- Keitzer, Rolf
- Burmester, Gerd-Rüdiger
- Buttgereit, Frank
- Radbruch, Andreas
- Hiepe, Falk
Producer: 20120208
In:
Annals of the rheumatic diseases vol. 71
Availability: No items available.
|
|
11279.
|
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. [electronic resource] by
- Lanasa, Mark C
- Davis, Patricia H
- Datto, Michael
- Li, Zhiguo
- Gockerman, Jon P
- Moore, Joseph O
- DeCastro, Carlos M
- Friedman, Daphne R
- Diehl, Louis F
- Rehder, Catherine
- Cook, Harry
- Daugherty, F Joseph
- Matta, Karen M B
- Weinberg, J Brice
- Rizzieri, David
Producer: 20120525
In:
Leukemia & lymphoma vol. 53
Availability: No items available.
|
|
11280.
|
|